Drug Profile
Research programme: hepatitis E and human papilloma virus vaccines - Chongqing Zhifei/Hong Kong University
Alternative Names: HEV vaccine - Chongquing Zhifei/Hong Kong University; HPV vaccine - Chongqing Zhifei/Hong Kong UniversityLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Chongqing Zhifei Biological Products; Hong Kong University of Science and Technology
- Developer Chongqing Zhifei Biological Products
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis E; Human papillomavirus infections
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Prevention) in China (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Hepatitis-E(Prevention) in China (Parenteral)
- 17 Jul 2016 Preclinical development in Hepatitis E virus prevention is ongoing in China